

Seung U Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7017261/publications.pdf>

Version: 2024-02-01

363
papers

11,645
citations

36303

51
h-index

49909

87
g-index

373
all docs

373
docs citations

373
times ranked

10852
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873. | 3.7 | 759 |
| 2 | Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85. | 2.8 | 358 |
| 3 | Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78. | 17.8 | 330 |
| 4 | Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894. | 7.3 | 329 |
| 5 | Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). <i>Journal of Hepatology</i> , 2015, 63, 486-493. | 3.7 | 264 |
| 6 | Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , 2016, 63, 776-786. | 7.3 | 261 |
| 7 | Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44930. | 2.5 | 242 |
| 8 | Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2138-2147.e10. | 4.4 | 237 |
| 9 | KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 363-401. | 8.9 | 152 |
| 10 | Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310. | 3.7 | 148 |
| 11 | Controlled attenuation parameter ($\langle \text{CAP} \rangle$) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109. | 3.9 | 143 |
| 12 | A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464. | 3.7 | 131 |
| 13 | Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763. | 2.3 | 122 |
| 14 | The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 556-563. | 3.7 | 122 |
| 15 | Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859. | 7.3 | 121 |
| 16 | Revision and update on clinical practice guideline for liver cirrhosis. <i>The Korean Journal of Hepatology</i> , 2012, 18, 1. | 1.5 | 120 |
| 17 | Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249. | 0.4 | 120 |
| 18 | The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98. | 2.8 | 117 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766. | 7.3 | 97 |
| 20 | How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71. | 2.2 | 94 |
| 21 | Clinical applications of transient elastography. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 163. | 8.9 | 93 |
| 22 | Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127. | 3.9 | 91 |
| 23 | Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1682-1691. | 2.3 | 90 |
| 24 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478. | 2.3 | 88 |
| 25 | Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e36676. | 2.5 | 84 |
| 26 | Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1343-1350. | 3.7 | 83 |
| 27 | Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839. | 5.1 | 78 |
| 28 | Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , 2008, 2, 471-7. | 4.2 | 77 |
| 29 | What are "true normal" liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274. | 3.9 | 76 |
| 30 | Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107. | 3.9 | 76 |
| 31 | Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834. | 2.8 | 71 |
| 32 | Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286. | 1.5 | 70 |
| 33 | Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353. | 1.5 | 68 |
| 34 | Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595. | 0.4 | 68 |
| 35 | Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384. | 2.5 | 67 |
| 36 | A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 855-862. | 3.7 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. <i>World Journal of Gastroenterology</i> , 2013, 19, 1890. | 3.3 | 67 |
| 38 | Liver Stiffness Measurement in Combination With Noninvasive Markers for the Improved Diagnosis of B-viral Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 267-271. | 2.2 | 66 |
| 39 | Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255. | 3.9 | 66 |
| 40 | Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99. | 3.9 | 64 |
| 41 | From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 257-269. | 8.9 | 64 |
| 42 | Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964. | 2.5 | 64 |
| 43 | Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. <i>Gut and Liver</i> , 2014, 8, 58-63. | 2.9 | 64 |
| 44 | Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358. | 2.5 | 62 |
| 45 | Prognostic value of α -fetoprotein and des- γ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , 2013, 13, 5. | 2.6 | 60 |
| 46 | Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575. | 2.8 | 59 |
| 47 | Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1. | 4.4 | 59 |
| 48 | Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1384-1390. | 2.8 | 57 |
| 49 | Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. <i>Liver International</i> , 2015, 35, 1103-1115. | 3.9 | 57 |
| 50 | Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 23-31. | 3.4 | 55 |
| 51 | Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 130-136. | 2.8 | 53 |
| 52 | Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653. | 1.5 | 53 |
| 53 | Liver stiffness measurement using FibroScan [®] is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , 2009, 29, 810-815. | 3.9 | 51 |
| 54 | Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 335-348. | 3.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 219. | 3.3 | 51 |
| 56 | Congestive hepatopathy after Fontan operation and related factors assessed by transient elastography. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1498-1505. | 0.8 | 50 |
| 57 | The Accuracy of Noninvasive Methods in Predicting the Development of Hepatocellular Carcinoma and Hepatic Decompensation in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 518-525. | 2.2 | 49 |
| 58 | Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation. <i>PLoS ONE</i> , 2012, 7, e32233. | 2.5 | 49 |
| 59 | Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162. | 0.8 | 49 |
| 60 | Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158. | 3.3 | 48 |
| 61 | An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318. | 3.7 | 48 |
| 62 | Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 498-505. | 3.7 | 47 |
| 63 | Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis Research and Therapy</i> , 2012, 14, R232. | 3.5 | 45 |
| 64 | Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825. | 2.5 | 45 |
| 65 | Acoustic Radiation Force Impulse Measurement in Renal Transplantation. <i>Medicine (United States)</i> , 2015, 94, e1590. | 1.0 | 45 |
| 66 | Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1008-1017. | 3.9 | 44 |
| 67 | Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204. | 3.7 | 43 |
| 68 | Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma. <i>Oncotarget</i> , 0, 7, 41798-41810. | 1.8 | 43 |
| 69 | Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , 2010, 4, 673-680. | 4.2 | 42 |
| 70 | Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351. | 0.8 | 42 |
| 71 | The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: A multicenter, prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 171-178. | 2.8 | 42 |
| 72 | Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544. | 2.2 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Prognostic Significance of ¹⁸ F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 509-516. | 5.0 | 42 |
| 74 | Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891. | 0.4 | 42 |
| 75 | Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511. | 7.0 | 38 |
| 76 | Comparison of treatment outcomes between balloon-occluded retrograde transvenous obliteration and transjugular intrahepatic portosystemic shunt for gastric variceal bleeding hemostasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1487-1494. | 2.8 | 38 |
| 77 | Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: Culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 122-128. | 2.8 | 37 |
| 78 | Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919. | 7.3 | 37 |
| 79 | Validation of PACE model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795. | 3.9 | 37 |
| 80 | <i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887. | 3.9 | 37 |
| 81 | Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229. | 2.8 | 37 |
| 82 | Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 300-312. | 3.7 | 37 |
| 83 | Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509. | 3.7 | 37 |
| 84 | Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299. | 2.9 | 37 |
| 85 | Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727. | 2.8 | 36 |
| 86 | Role of surgical resection for multiple hepatocellular carcinomas. <i>World Journal of Gastroenterology</i> , 2013, 19, 366. | 3.3 | 36 |
| 87 | Impact of Spontaneous Hepatocellular Carcinoma Rupture on Recurrence Pattern and Long-term Surgical Outcomes after Partial Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 2070-2078. | 1.6 | 36 |
| 88 | Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496. | 2.8 | 36 |
| 89 | Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856. | 1.6 | 35 |
| 90 | Combined measurement of preoperative Î ₁ -fetoprotein and desÎ ₁ -carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 2332-2341. | 5.1 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Response Rates to Medical Treatments and Long-term Clinical Outcomes of Nonsurgical Patients With Intestinal Behçet Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e116-e122. | 2.2 | 34 |
| 92 | Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062. | 3.9 | 34 |
| 93 | Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581. | 2.3 | 34 |
| 94 | Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 165-173. | 2.3 | 33 |
| 95 | Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296. | 2.2 | 33 |
| 96 | Prediction of the varices needing treatment with noninvasive tests in patients with compensated advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 1071-1079. | 3.9 | 33 |
| 97 | Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689. | 2.5 | 33 |
| 98 | Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223. | 3.9 | 32 |
| 99 | A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009. | 2.5 | 32 |
| 100 | Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6. | 4.4 | 32 |
| 101 | Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. <i>Acta Radiologica</i> , 2017, 58, 131-139. | 1.1 | 32 |
| 102 | Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39. | 1.7 | 32 |
| 103 | Unhealthy lifestyle habits and physical inactivity among Asian patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731. | 3.9 | 32 |
| 104 | The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885. | 2.2 | 31 |
| 105 | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 402-412. | 8.9 | 31 |
| 106 | Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293. | 8.9 | 31 |
| 107 | A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32. | 8.9 | 31 |
| 108 | Transient elastography in chronic hepatitis B: An Asian perspective. <i>World Journal of Gastroenterology</i> , 2010, 16, 5173. | 3.3 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322. | 2.8 | 30 |
| 110 | Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837. | 2.5 | 30 |
| 111 | Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788. | 2.8 | 29 |
| 112 | Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 313-321. | 3.9 | 29 |
| 113 | Red cell volume distribution width to platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 24-30. | 3.9 | 29 |
| 114 | External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630. | 3.9 | 29 |
| 115 | Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 598-607. | 1.7 | 28 |
| 116 | Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189. | 3.9 | 28 |
| 117 | Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542. | 2.8 | 28 |
| 118 | Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328. | 1.0 | 28 |
| 119 | Cryoablation of Hepatocellular Carcinoma with High-Risk for Percutaneous Ablation: Safety and Efficacy. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1447-1454. | 2.0 | 28 |
| 120 | Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178. | 7.3 | 28 |
| 121 | Inhibition of tumour angiogenesis and growth by small hairpin HIF-1 and IL-8 in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642. | 3.9 | 27 |
| 122 | Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2013, 8, e69166. | 2.5 | 26 |
| 123 | Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469. | 2.8 | 26 |
| 124 | Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482. | 3.3 | 26 |
| 125 | The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55. | 2.2 | 26 |
| 126 | MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928. | 2.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884. | 2.5 | 25 |
| 128 | Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. <i>PLoS ONE</i> , 2015, 10, e0139227. | 2.5 | 25 |
| 129 | Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032. | 2.8 | 25 |
| 130 | A Case of Hepatocellular Carcinoma Within Hepatocellular Adenoma in a Non-Cirrhotic Male. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 147. | 1.7 | 25 |
| 131 | Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. <i>PLoS ONE</i> , 2014, 9, e99167. | 2.5 | 24 |
| 132 | Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 272-278. | 2.2 | 24 |
| 133 | Early α -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 39. | 3.7 | 24 |
| 134 | Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. <i>Oncotarget</i> , 2017, 8, 113213-113224. | 1.8 | 24 |
| 135 | Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 828-834. | 2.9 | 24 |
| 136 | Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 503-510. | 2.8 | 24 |
| 137 | Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1. | 4.4 | 24 |
| 138 | Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. <i>Medicine (United States)</i> , 2016, 95, e2985. | 1.0 | 23 |
| 139 | Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , 2017, 11, 268-276. | 4.2 | 23 |
| 140 | Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. <i>Journal of Viral Hepatitis</i> , 2017, 24, 141-147. | 2.0 | 23 |
| 141 | Genetically Engineered Mouse Models for Liver Cancer. <i>Cancers</i> , 2020, 12, 14. | 3.7 | 23 |
| 142 | An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. <i>Liver International</i> , 2020, 40, 1736-1743. | 3.9 | 23 |
| 143 | Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. <i>Hepatology International</i> , 2012, 6, 763-769. | 4.2 | 22 |
| 144 | Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , 2013, 6, 1463. | 2.0 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 347. | 2.0 | 22 |
| 146 | Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730. | 3.9 | 22 |
| 147 | Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686. | 3.9 | 22 |
| 148 | Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325. | 2.8 | 22 |
| 149 | Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127. | 2.9 | 22 |
| 150 | Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984. | 1.8 | 22 |
| 151 | Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847. | 2.8 | 21 |
| 152 | Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527. | 3.7 | 21 |
| 153 | Metabolic Dysfunctionâ€Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00435. | 2.5 | 21 |
| 154 | Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. <i>Anticancer Research</i> , 2011, 31, 4641-6. | 1.1 | 21 |
| 155 | Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477. | 1.0 | 20 |
| 156 | Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191. | 1.9 | 20 |
| 157 | Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240. | 2.5 | 20 |
| 158 | Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508. | 3.3 | 20 |
| 159 | Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222. | 12.1 | 20 |
| 160 | Serum <i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 33-44. | 8.9 | 20 |
| 161 | Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399. | 8.9 | 20 |
| 162 | The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774. | 2.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , 2009, 29, 760-766. | 3.9 | 19 |
| 164 | Clinical Application of Liver Stiffness Measurement Using Transient Elastography: A Surgical Perspective. <i>Digestion</i> , 2013, 88, 258-265. | 2.3 | 19 |
| 165 | Role of splenectomy in patients with hepatocellular carcinoma and hypersplenism. <i>ANZ Journal of Surgery</i> , 2013, 83, 865-870. | 0.7 | 19 |
| 166 | Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment. <i>PLoS ONE</i> , 2013, 8, e52720. | 2.5 | 19 |
| 167 | Knockdown of HIF-1 α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 85-95. | 4.9 | 19 |
| 168 | Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 275. | 1.0 | 19 |
| 169 | Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 523-530. | 3.0 | 19 |
| 170 | Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115. | 0.8 | 19 |
| 171 | Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304. | 8.9 | 19 |
| 172 | Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635. | 2.9 | 19 |
| 173 | Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456. | 2.3 | 18 |
| 174 | Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , 2015, 35, 455-462. | 3.9 | 18 |
| 175 | Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158. | 2.3 | 18 |
| 176 | Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1079-1086. | 2.8 | 18 |
| 177 | Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7. | 4.4 | 18 |
| 178 | Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480. | 1.7 | 18 |
| 179 | Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092. | 4.2 | 18 |
| 180 | Bariatric Arterial Embolization with Non-spherical Polyvinyl Alcohol Particles for Ghrelin Suppression in a Swine Model. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 744-749. | 2.0 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2. | 4.4 | 17 |
| 182 | Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036. | 2.5 | 17 |
| 183 | Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77. | 1.8 | 17 |
| 184 | MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy. <i>American Journal of Roentgenology</i> , 2020, 215, 1354-1362. | 2.2 | 17 |
| 185 | Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoteric acid-enhanced magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 4492-4503. | 4.5 | 17 |
| 186 | Dynamics of the Liver Stiffness Value Using Transient Elastography during the Perioperative Period in Patients with Valvular Heart Disease. <i>PLoS ONE</i> , 2014, 9, e92795. | 2.5 | 17 |
| 187 | Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275. | 2.9 | 17 |
| 188 | Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 358-369.e12. | 4.4 | 17 |
| 189 | Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 923-926. | 1.6 | 16 |
| 190 | How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements. <i>Yonsei Medical Journal</i> , 2012, 53, 337. | 2.2 | 16 |
| 191 | Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011. | 2.8 | 16 |
| 192 | Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663. | 3.9 | 16 |
| 193 | Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36. | 2.9 | 16 |
| 194 | Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , 2010, 28, 802-811. | 1.8 | 15 |
| 195 | Optimal Time for Restoring the Reliability of Liver Stiffness Measurement in Patients With Chronic Hepatitis B Experiencing Acute Exacerbation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 602-607. | 2.2 | 15 |
| 196 | Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406. | 0.8 | 15 |
| 197 | Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1. | 0.5 | 15 |
| 198 | Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900. | 4.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578. | 2.0 | 15 |
| 200 | Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101344. | 2.9 | 15 |
| 201 | Normal enhanced liver fibrosis (<scp>ELF</scp>) values in apparently healthy subjects undergoing a health checkup and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713. | 3.9 | 14 |
| 202 | Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242. | 2.3 | 14 |
| 203 | Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434. | 1.0 | 14 |
| 204 | Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624. | 1.5 | 14 |
| 205 | Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1201-1212. | 3.7 | 14 |
| 206 | Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298. | 1.6 | 14 |
| 207 | Successful hemostasis of intractable rectal variceal bleeding using variceal embolization. <i>World Journal of Gastroenterology</i> , 2015, 21, 2558. | 3.3 | 14 |
| 208 | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797. | 2.9 | 14 |
| 209 | Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 425-472. | 8.9 | 14 |
| 210 | Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534. | 2.8 | 13 |
| 211 | Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290. | 1.5 | 13 |
| 212 | An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322. | 2.0 | 13 |
| 213 | Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140. | 2.5 | 13 |
| 214 | Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 956-958.e2. | 4.4 | 13 |
| 215 | Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 29. | 8.9 | 13 |
| 216 | Non-invasive prediction of forthcoming cirrhosis-related complications. <i>World Journal of Gastroenterology</i> , 2014, 20, 2613. | 3.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Noninvasive assessment of liver fibrosis: Time to move from cross-sectional studies to longitudinal ones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1472-1473. | 2.8 | 12 |
| 218 | Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807. | 4.4 | 12 |
| 219 | Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713. | 2.8 | 12 |
| 220 | Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334. | 2.9 | 12 |
| 221 | Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205. | 2.9 | 12 |
| 222 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 1328-1336. | 4.2 | 12 |
| 223 | Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2022, 65, 518-527. | 6.3 | 12 |
| 224 | Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. <i>Intervirology</i> , 2012, 55, 112-118. | 2.8 | 11 |
| 225 | Acute Variceal Hemorrhage in Patients with Liver Cirrhosis: Weekend versus Weekday Admissions. <i>Yonsei Medical Journal</i> , 2012, 53, 318. | 2.2 | 11 |
| 226 | Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial. <i>Yonsei Medical Journal</i> , 2012, 53, 328. | 2.2 | 11 |
| 227 | Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 755. | 2.0 | 11 |
| 228 | Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 501-511. | 3.0 | 11 |
| 229 | The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years. <i>Journal of Clinical Medicine</i> , 2019, 8, 2065. | 2.4 | 11 |
| 230 | Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65. | 1.6 | 11 |
| 231 | Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429. | 2.9 | 11 |
| 232 | Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759. | 2.5 | 11 |
| 233 | Silencing of Hypoxia-Inducible Factor-1 α Induces Anti-Tumor Effects in Hepatoma Cell Lines under Tumor Hypoxia. <i>PLoS ONE</i> , 2014, 9, e103304. | 2.5 | 11 |
| 234 | Maintaining remission in lamivudine-resistant patients with a virological response to adefovir after lamivudine therapy. <i>Liver International</i> , 2014, 34, 1543-1549. | 3.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261. | 8.9 | 10 |
| 236 | Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1176-1185.e3. | 0.8 | 10 |
| 237 | Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. <i>European Radiology</i> , 2019, 29, 1022-1031. | 4.5 | 9 |
| 238 | The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 375. | 2.4 | 9 |
| 239 | Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322. | 2.4 | 9 |
| 240 | Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414. | 3.7 | 9 |
| 241 | Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747. | 2.3 | 9 |
| 242 | A qualitative study of self-management experiences in people with non-alcoholic fatty liver disease. <i>Nursing Open</i> , 2021, 8, 3135-3142. | 2.4 | 9 |
| 243 | Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16. | 4.4 | 9 |
| 244 | Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2015, 9, 776. | 2.9 | 9 |
| 245 | Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B. <i>Liver International</i> , 2022, 42, 1017-1026. | 3.9 | 9 |
| 246 | Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirology</i> , 2008, 51, 293-298. | 2.8 | 8 |
| 247 | Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1027-1034. | 5.0 | 8 |
| 248 | Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , 2017, 11, 292-299. | 4.2 | 8 |
| 249 | Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668. | 2.3 | 8 |
| 250 | Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363. | 2.6 | 8 |
| 251 | Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425. | 3.7 | 8 |
| 252 | Hepatic Fibrosis Assessed Using Fibrosis-4 Index Is Predictive of All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2020, Volume 15, 831-839. | 2.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104. | 2.0 | 8 |
| 254 | No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553. | 2.0 | 8 |
| 255 | Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567. | 3.7 | 8 |
| 256 | Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA $\geq 2,000$ IU/mL. <i>American Journal of Gastroenterology</i> , 2022, 117, 288-294. | 0.4 | 8 |
| 257 | Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2018, 12, 190-200. | 2.9 | 8 |
| 258 | Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330. | 2.9 | 8 |
| 259 | Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190. | 2.6 | 8 |
| 260 | Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396. | 3.7 | 8 |
| 261 | The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials. <i>Obesity Reviews</i> , 2022, 23, e13464. | 6.5 | 8 |
| 262 | Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431. | 2.5 | 7 |
| 263 | Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247. | 2.8 | 7 |
| 264 | Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502. | 5.0 | 7 |
| 265 | Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613. | 2.5 | 7 |
| 266 | A multicentre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358. | 2.0 | 7 |
| 267 | Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060. | 2.0 | 7 |
| 268 | Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. <i>European Radiology</i> , 2021, 31, 4813-4823. | 4.5 | 7 |
| 269 | Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 1828. | 3.7 | 7 |
| 270 | Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927. | 3.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926. | 1.8 | 7 |
| 272 | Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296. | 2.0 | 7 |
| 273 | The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B. <i>Hepato-Gastroenterology</i> , 2010, 57, 832-8. | 0.5 | 7 |
| 274 | Non-invasive assessment of liver fibrosis: The gap between ideal and real. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 937-939. | 2.8 | 6 |
| 275 | Acoustic radiation force impulse elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 215-216. | 1.6 | 6 |
| 276 | Can transient elastography be used for the management of chronic hepatitis B patients?. <i>Liver International</i> , 2012, 32, 528-530. | 3.9 | 6 |
| 277 | Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671. | 3.3 | 6 |
| 278 | Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582. | 1.8 | 6 |
| 279 | Diagnostic Performance of Serum Asialo- α 1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 74, 341. | 0.4 | 6 |
| 280 | Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345. | 0.9 | 6 |
| 281 | Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940. | 2.0 | 6 |
| 282 | Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12. | 2.2 | 6 |
| 283 | External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958. | 2.0 | 6 |
| 284 | Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412. | 3.7 | 6 |
| 285 | Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104. | 2.5 | 6 |
| 286 | Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, . | 2.8 | 6 |
| 287 | Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892. | 3.7 | 6 |
| 288 | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385. | 3.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 241-247. | 1.3 | 6 |
| 290 | Graft Function Measured by Transient Elastography in Living Donor Liver Transplantation: Preliminary. <i>Transplantation Proceedings</i> , 2013, 45, 3028-3031. | 0.6 | 5 |
| 291 | The Use of Health Functional Foods in Gastrointestinal Cancer Patients. <i>Clinical Nutrition Research</i> , 2013, 2, 19. | 1.2 | 5 |
| 292 | Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22. | 0.2 | 5 |
| 293 | Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688. | 0.9 | 5 |
| 294 | Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90. | 5.0 | 5 |
| 295 | Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416. | 3.4 | 5 |
| 296 | Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485. | 2.8 | 5 |
| 297 | Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207. | 2.8 | 5 |
| 298 | Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 48-57. | 2.2 | 5 |
| 299 | Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701. | 2.9 | 5 |
| 300 | Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214. | 2.9 | 5 |
| 301 | Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74. | 0.8 | 5 |
| 302 | Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145. | 2.2 | 4 |
| 303 | Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628. | 3.3 | 4 |
| 304 | Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89. | 3.9 | 4 |
| 305 | Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372. | 2.0 | 4 |
| 306 | Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1. | 2.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893. | 1.6 | 4 |
| 308 | Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 367-369. | 8.9 | 4 |
| 309 | Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67. | 3.7 | 4 |
| 310 | Compensated heart failure does not always alleviate overestimation of liver stiffness by transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 385-387. | 1.6 | 3 |
| 311 | Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model. <i>Digestive Diseases and Sciences</i> , 2016, 61, 507-516. | 2.3 | 3 |
| 312 | Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438. | 2.3 | 3 |
| 313 | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133. | 2.5 | 3 |
| 314 | Development and initial validation of the nonalcoholic fatty liver disease self-management questionnaire. <i>Research in Nursing and Health</i> , 2021, 44, 844-853. | 1.6 | 3 |
| 315 | Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105. | 2.5 | 3 |
| 316 | Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 255. | 8.9 | 3 |
| 317 | Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353. | 1.7 | 3 |
| 318 | Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101362. | 2.9 | 3 |
| 319 | Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Digestion</i> , 2013, 87, 196-203. | 2.3 | 2 |
| 320 | Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 514-515. | 1.6 | 2 |
| 321 | The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 208-214. | 2.8 | 2 |
| 322 | Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 333-334. | 3.7 | 2 |
| 323 | Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544. | 1.6 | 2 |
| 324 | Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747. | 1.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 5-7. | 4.2 | 2 |
| 326 | Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2020, 73, 1270-1271. | 3.7 | 2 |
| 327 | Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2020, 158, 2310-2311. | 1.3 | 2 |
| 328 | Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy. <i>Journal of Hepatology</i> , 2020, 73, 222-223. | 3.7 | 2 |
| 329 | Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977. | 2.2 | 2 |
| 330 | A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75. | 1.1 | 2 |
| 331 | The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476. | 3.7 | 2 |
| 332 | Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 116, 114-121. | 3.3 | 2 |
| 333 | Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1877-1880.e3. | 4.4 | 2 |
| 334 | Acoustic radiation force impulse elastography is useful to exclude nonliver-related ascites. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1080-1081. | 1.6 | 1 |
| 335 | Reply to "The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?". <i>Journal of Hepatology</i> , 2015, 63, 281-282. | 3.7 | 1 |
| 336 | Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 676-685. | 2.2 | 1 |
| 337 | Radiologic Evaluation of Non-Alcoholic Fatty Liver Disease in Diabetic Patient. <i>Journal of Korean Diabetes</i> , 2017, 18, 88. | 0.3 | 1 |
| 338 | Pharmacologic Treatment Using Non-Hypoglycemic Agents for Nonalcoholic Fatty Liver Disease. <i>Journal of Korean Diabetes</i> , 2018, 19, 97. | 0.3 | 1 |
| 339 | Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 913-914. | 3.7 | 1 |
| 340 | Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment" still an open issue. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 889-890. | 3.7 | 1 |
| 341 | Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-related Hepatocellular Carcinoma After Surgical Resection. <i>Hepatology</i> , 2021, 73, 466-466. | 7.3 | 1 |
| 342 | Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283. | 1.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Predictors of Sarcopenia in an Obese Asian Population. <i>Nutrition and Cancer</i> , 2022, 74, 505-514. | 2.0 | 1 |
| 344 | Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485. | 2.9 | 1 |
| 345 | External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711. | 3.7 | 1 |
| 346 | Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. <i>Diagnostics</i> , 2022, 12, 441. | 2.6 | 1 |
| 347 | Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 576-584. | 1.6 | 1 |
| 348 | Fibrotic burden during antiviral therapy for chronic hepatitis B, not <scp>ALT</scp> level, independently predicts liver cancer risk. <i>Liver International</i> , 2022, 42, 1902-1906. | 3.9 | 1 |
| 349 | Transient elastography in real practice: A time for action?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1134-1135. | 2.8 | 0 |
| 350 | Can Non-invasive Fibrosis Assessment Predict Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2014, 64, 250. | 0.4 | 0 |
| 351 | Reply to "Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue". <i>Journal of Hepatology</i> , 2015, 63, 1532. | 3.7 | 0 |
| 352 | Reply to "prognostic model for patients receiving arterial embolization for hepatocellular carcinoma: issues to consider". <i>Liver International</i> , 2016, 36, 312-312. | 3.9 | 0 |
| 353 | Reply. <i>Hepatology</i> , 2016, 63, 672-673. | 7.3 | 0 |
| 354 | IDDF2018-ABS-0028...Risk assessment in patients treated with tace due to recurred hepatocellular carcinoma after curative resection. , 2018, , . | | 0 |
| 355 | IDDF2018-ABS-0027...Influence of hepatic steatosis on the treatment outcomes of entecavir and tenofovir in patients with chronic hepatitis B. , 2018, , . | | 0 |
| 356 | Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2020, 73, 988-989. | 3.7 | 0 |
| 357 | Advanced Stage Hepatocellular Carcinoma Successfully Treated with Liver-directed Concurrent Chemoradiotherapy and Sequential Transarterial Radio-embolization. <i>Journal of Liver Cancer</i> , 2021, 21, 97-103. | 1.1 | 0 |
| 358 | Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15678-e15678. | 1.6 | 0 |
| 359 | Can Magnetic Resonance Elastography Fill a Niche in the Market for Noninvasive Assessment of Liver Fibrosis?. <i>Gut and Liver</i> , 2017, 11, 321-322. | 2.9 | 0 |
| 360 | Clinical Implications of Shear Wave Elastography in Patients with Chronic Hepatitis B. <i>Journal of Clinical Ultrasound</i> , 2018, 3, 45-49. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Authors'™ response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 574-574. | 2.0 | 0 |
| 362 | Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4788-4806. | 1.4 | 0 |
| 363 | Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune-tolerant phase authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1094-1095. | 3.7 | 0 |